Taichi Isobe
Overview
Explore the profile of Taichi Isobe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsubara J, Li Y, Koul S, Mukohyama J, Salazar L, Isobe T, et al.
bioRxiv
. 2025 Feb;
PMID: 39896677
Background: (CRCs) are seldom eradicated by cytotoxic chemotherapy. Cancer cells with stem-like functional properties, often referred to as "" (CSCs), display preferential resistance to several anti-tumor agents used in cancer...
2.
Matsumura T, Tsuchihashi K, Yamamoto T, Jinnouchi F, Kusano W, Kusumoto Y, et al.
Intern Med
. 2024 Oct;
PMID: 39428537
A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and...
3.
Tanoue K, Ohmura H, Uehara K, Ito M, Yamaguchi K, Tsuchihashi K, et al.
Nat Commun
. 2024 Oct;
15(1):9033.
PMID: 39426955
Despite the success of immune checkpoint blockade (ICB) therapy for esophageal squamous cell cancer, the key immune cell populations that affect ICB efficacy remain unclear. Here, imaging mass cytometry of...
4.
Furukawa K, Ohmura H, Moriyama S, Uehara K, Ito M, Tsuchihashi K, et al.
Jpn J Clin Oncol
. 2024 Oct;
55(2):113-122.
PMID: 39385509
Background: Malignant primary cardiac tumors require multimodal approaches including surgery, chemotherapy and radiotherapy, but these treatments can be associated with cardiovascular complications. However, few reports have described the cardiovascular complications...
5.
Yamaguchi K, Ito M, Isobe T, Koreishi S, Taguchi R, Uehara K, et al.
JCO Precis Oncol
. 2024 May;
8:e2300681.
PMID: 38748981
Purpose: The impact of genomic alterations on response and resistance to trastuzumab deruxtecan (T-DXd) has not been elucidated. Thus, we sought to identify factors predicting sensitivity to T-DXd in gastric...
6.
Tsuchihashi K, Ito M, Arita S, Kusaba H, Kusano W, Matsumura T, et al.
BMC Cancer
. 2023 Oct;
23(1):1046.
PMID: 37904096
Background: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the...
7.
Uehara K, Tanoue K, Yamaguchi K, Ohmura H, Ito M, Matsushita Y, et al.
Cancer Immunol Immunother
. 2023 Aug;
72(11):3543-3558.
PMID: 37550428
Combined immune checkpoint blockade (ICB) is effective therapy for renal cell carcinoma (RCC). However, the dynamic changes in circulating B cells induced by combined ICB have not been clarified. The...
8.
Nakano M, Taguchi R, Kikushige Y, Isobe T, Miyawaki K, Mizuno S, et al.
Cancer Sci
. 2023 Mar;
114(7):2895-2906.
PMID: 36945114
The cancer stem cell (CSC) theory features typically rare self-renewing subpopulations that reconstitute the heterogeneous tumor. Identification of molecules that characterize the features of CSCs is a key imperative for...
9.
Yoshihiro T, Ariyama H, Yamaguchi K, Imajima T, Yamaga S, Tsuchihashi K, et al.
Cancer Sci
. 2022 Sep;
113(12):4207-4218.
PMID: 36053154
Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment of colorectal cancer (CRC), preclinical studies...
10.
Kusaba H, Moriyama S, Hieda M, Ito M, Ohmura H, Isobe T, et al.
Jpn J Clin Oncol
. 2022 Jun;
52(10):1183-1190.
PMID: 35766165
Background: The incidence of venous thromboembolism has been reported as 20% in cancer patients. Anticoagulation therapy is the standard treatment for venous thromboembolism. On the other hand, bleeding should be...